|Articles|March 1, 2006

Upcoming for ADHD meds: Black box warning?

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

CBT and fluoxetine show comparable improvement for pediatric anxiety

CBT and fluoxetine show comparable improvement for pediatric anxiety

ByBradley Peterson, MD

August 26th 2026

FDA approves dolutegravir dispersible tablets for HIV-infected newborns

FDA approves dolutegravir dispersible tablets for HIV-infected newborns

ByMorgan Ebert, Executive Editor

August 26th 2026

FDA authorizes Avulux light-filtering lenses for migraine-associated light sensitivity in patients 12 and older

FDA authorizes Avulux light-filtering lenses for migraine-associated light sensitivity in patients 12 and older

ByMorgan Ebert, Executive Editor

August 26th 2026

FDA authorizes first dual glucose-ketone monitor for children as young as 2

FDA authorizes first dual glucose-ketone monitor for children as young as 2

ByMorgan Ebert, Executive Editor

August 25th 2026

FDA approves nipocalimab as first treatment for warm autoimmune hemolytic anemia

FDA approves nipocalimab as first treatment for warm autoimmune hemolytic anemia

ByMorgan Ebert, Executive Editor

August 25th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

FDA authorizes Avulux light-filtering lenses for migraine-associated light sensitivity in patients 12 and older

FDA approves dolutegravir dispersible tablets for HIV-infected newborns

Mental health treatment increases among US children and teens

CBT and fluoxetine show comparable improvement for pediatric anxiety

Lebrikizumab phase 3 data show improvements in atopic dermatitis symptoms, itch in children